Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/899866/000089986613000060/alxn10k12312012.htm
SEC Filings
ALXN Annual Reports
ALXN Quarterly Reports
10-Q Quarterly Report April 2021
10-Q Quarterly Report October 2020
10-Q Quarterly Report July 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report October 2019
10-Q Quarterly Report July 2019
10-Q Quarterly Report April 2019
10-Q Quarterly Report October 2018
10-Q Quarterly Report October 2018
10-Q Quarterly Report July 2018
10-Q Quarterly Report April 2021
10-Q Quarterly Report October 2020
10-Q Quarterly Report July 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report October 2019
10-Q Quarterly Report July 2019
10-Q Quarterly Report April 2019
10-Q Quarterly Report October 2018
10-Q Quarterly Report October 2018
10-Q Quarterly Report July 2018
ALXN Corporate News
Bylaw Change
Change in Assets
Change in Control
Ending Agreement
Event for Officers
Financial Exhibit
Listing Status
Security Holders Change July 2021
Earnings Release July 2021
Financial Exhibit
Other Events
Vote of Security Holders May 2021
Other Events May 2021
Earnings Release
Financial Exhibit April 2021
Financial Exhibit
Other Events March 2021
Event for Officers February 2021
Earnings Release
Financial Exhibit February 2021
Earnings Release
Financial Exhibit
Regulated Disclosure January 2021
Financial Exhibit
New Agreement
Other Events December 2020
Bylaw Change
Change in Assets
Change in Control
Ending Agreement
Event for Officers
Financial Exhibit
Listing Status
Security Holders Change
Change in Assets
Change in Control
Ending Agreement
Event for Officers
Financial Exhibit
Listing Status
Security Holders Change
July 2021
Earnings Release
July 2021
Financial Exhibit
Other Events
Vote of Security Holders
Other Events
Vote of Security Holders
May 2021
Other Events
May 2021
Earnings Release
Financial Exhibit
Financial Exhibit
April 2021
Financial Exhibit
Other Events
Other Events
March 2021
Event for Officers
February 2021
Earnings Release
Financial Exhibit
Financial Exhibit
February 2021
Earnings Release
Financial Exhibit
Regulated Disclosure
Financial Exhibit
Regulated Disclosure
January 2021
Financial Exhibit
New Agreement
Other Events
New Agreement
Other Events
December 2020
ALXN Merger Prospectus
425 Merger Prospectus July 2021
425 Merger Prospectus July 2021
425 Merger Prospectus July 2021
425 Merger Prospectus July 2021
425 Merger Prospectus June 2021
425 Merger Prospectus June 2021
425 Merger Prospectus June 2021
425 Merger Prospectus May 2021
425 Merger Prospectus May 2021
425 Merger Prospectus May 2021
425 Merger Prospectus July 2021
425 Merger Prospectus July 2021
425 Merger Prospectus July 2021
425 Merger Prospectus July 2021
425 Merger Prospectus June 2021
425 Merger Prospectus June 2021
425 Merger Prospectus June 2021
425 Merger Prospectus May 2021
425 Merger Prospectus May 2021
425 Merger Prospectus May 2021
Last10K.com | 10-K Annual Report Tue Feb 19 2013
Contacts :
Alexion Pharmaceuticals, Inc. Irving Adler Executive Director, Corporate Communications (203) 271-8210 | Alexion Pharmaceuticals, Inc. Kim Diamond (Media) Director, Corporate Communications (203) 439-9600 | Rx Communications (Investors) Rhonda Chiger (917) 322-2569 |
Alexion Reports Fourth Quarter and Full Year 2012 Results
- Soliris® (eculizumab) Net Product Sales Increased 45 Percent to $1.134 Billion in 2012 -
- Continued Steady Growth of Soliris in PNH -
- aHUS Launch Progresses with Increasing Number of New Patients Starting on Soliris -
- Pipeline Advances with Five Therapeutic Candidates Targeting Severe and Ultra-Rare Disorders -
Fourth Quarter 2012 Financial Highlights:
• | Q4 2012 net product sales increased 41 percent to $320.5 million, compared to $227.6 million in Q4 2011. |
• | Q4 2012 GAAP net income increased 68 percent to $81.0 million, or $0.40 per share, compared to Q4 2011 GAAP net income of $48.2 million, or $0.25 per share. |
• | Q4 2012 non-GAAP net income increased 52 percent to $122.3 million, or $0.60 per share, compared to Q4 2011 non-GAAP net income of $80.5 million, or $0.41 per share. |
Full-Year 2012 Financial Highlights:
• | 2012 net product sales increased 45 percent to $1.134 billion, compared to $783.4 million in 2011. |
• | 2012 GAAP net income increased 45 percent to $254.8 million, or $1.28 per share, compared to 2011 GAAP net income of $175.3 million, or $0.91 per share. |
• | 2012 non-GAAP net income increased 60 percent to $425.2 million, or $2.13 per share, compared to 2011 non-GAAP net income of $266.1 million, or $1.38 per share. |
CHESHIRE, Conn., February 14, 2013 -- Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the quarter and year ended December 31, 2012. For the three months ended December 31, 2012, Alexion Pharmaceuticals, Inc. ("Alexion" or the
1
The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 14, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Alexion Pharmaceuticals, Inc..
Assess how Alexion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Alexion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Document And Entity Information Document
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statement Of Comprehensive Income
Consolidated Statement Of Comprehensive Income (parentheticals)
Consolidated Statements Of Operations
Statement Of Cash Flows
Statement Of Shareholders' Equity
Statement Of Shareholders' Equity (parentheticals)
Accrued Expenses
Accrued Expenses (schedule Of Accrued Expenses) (details)
Accrued Expenses (tables)
Acquisitions
Acquisitions (acquisition Related Costs) (details)
Acquisitions (narrative) (details)
Acquisitions (pro Forma Financial Information Of Combined Results Of Operations) (details)
Acquisitions (purchase Price Allocation To Assets Acquired And Liabilities Assumed) (details)
Acquisitions (reconciliation Of Upfront Payments To Total Purchase Price) (details)
Acquisitions (tables)
Business Overview And Summary Of Significant Accounting Policies
Business Overview And Summary Of Significant Accounting Policies (accounts Receivable) (details)
Business Overview And Summary Of Significant Accounting Policies (comprehensive Income (loss)) (details)
Business Overview And Summary Of Significant Accounting Policies (earnings Per Common Share) (details)
Business Overview And Summary Of Significant Accounting Policies (inventories) (details)
Business Overview And Summary Of Significant Accounting Policies (narrative) (details)
Business Overview And Summary Of Significant Accounting Policies (policies)
Business Overview And Summary Of Significant Accounting Policies (tables)
Commitments And Contingencies
Commitments And Contingencies (narrative) (details)
Commitments And Contingencies (schedule Of Aggregate Future Minimum Annual Rental Payments) (details)
Commitments And Contingencies (schedule Of Minimum Fixed Payments Due Under License And Research And Development Agreements) (details)
Commitments And Contingencies (tables)
Debt
Debt (details)
Derivative Instruments And Hedging Activities
Derivative Instruments And Hedging Activities (narrative) (details)
Derivative Instruments And Hedging Activities (schedule Of Fair Value Of Outstanding Derivatives) (details)
Derivative Instruments And Hedging Activities (schedule Of Other Comprehensive Income And Earnings From Foreign Exchange Contracts) (details)
Derivative Instruments And Hedging Activities (tables)
Employee Benefit Plans
Employee Benefit Plans (narrative) (details)
Employee Benefit Plans (schedule Of Change In Benefit Obligation) (details)
Employee Benefit Plans (schedule Of Change In Plan Assets) (details)
Employee Benefit Plans (schedule Of Components Of Net Periodic Benefit Cost) (details)
Employee Benefit Plans (schedule Of Estimated Future Benefit Payments) (details)
Employee Benefit Plans (schedule Of Fair Value Of Plan Assets And Target Asset Allocation) (details)
Employee Benefit Plans (schedule Of Other Changes In Plan Assets And Benefit Obligations Recognized In Other Comprehensive Income) (details)
Employee Benefit Plans (schedule Of Weighted Average Assumptions Used To Calculate Net Periodic Benefit Cost And The Actuarial Present Value Of Projected Benefit Obligations) (details)
Employee Benefit Plans (tables)
Fair Value Measurement
Fair Value Measurement (schedule Of Acquisition-related Contingent Consideration) (details)
Fair Value Measurement (schedule Of Assets And Liabilites Measured At Fair Value) (details)
Fair Value Measurement (tables)
Income Taxes
Income Taxes (narrative) (details)
Income Taxes (reconciliation Of The Statutory U.s. Federal Income Tax Rate To Effective Income Tax Rate) (details)
Income Taxes (reconciliation Of Unrecognized Tax Benefits) (details)
Income Taxes (schedule Of Components Of Deferred Tax Assets And Liabilities) (details)
Income Taxes (schedule Of Components Of Income Tax Provision (benefit)) (details)
Income Taxes (schedule Of Income Tax Provision (benefit) On Income Before Income Taxes) (details)
Income Taxes (tables)
Intangible Assets And Goodwill
Intangible Assets And Goodwill (amortization Of Intangible Assets) (details)
Intangible Assets And Goodwill (schedule Of Changes In The Carrying Amount Of Goodwill) (details)
Intangible Assets And Goodwill (schedule Of Intangible Assets And Goodwill) (details)
Intangible Assets And Goodwill (tables)
Intangible Assets And Goodwill Narratives (details)
Prepaid Expenses And Other Assets
Prepaid Expenses And Other Assets (details)
Prepaid Expenses And Other Assets (tables)
Property, Plant And Equipment, Net
Property, Plant And Equipment, Net (details)
Property, Plant And Equipment, Net (tables)
Quarterly Financial Information (unaudited)
Quarterly Financial Information (unaudited) (details)
Quarterly Financial Information (unaudited) (tables)
Segment Information
Segment Information (details)
Segment Information (tables)
Stock Options And Restricted Stock
Stock Options And Restricted Stock (narrative) (details)
Stock Options And Restricted Stock (schedule Of Components Of Allocated Share-based Compensation Expense And Capitalization Of Share Based Compensation Expense) (details)
Stock Options And Restricted Stock (schedule Of Ranges Of Weighted Average Assumptions) (details)
Stock Options And Restricted Stock (schedule Of Status Of Non-vested Restricted Stock) (details)
Stock Options And Restricted Stock (schedule Of Status Of Stock Option Plans) (details)
Stock Options And Restricted Stock (tables)
Stockholders' Equity
Stockholders' Equity (details)
Subsequent Events
Subsequent Events (details)
Material Contracts, Statements, Certifications & more
Alexion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Exhibit 21.1: Subsidiaries Of Alexion Pharmaceuticals, Inc.
Exhibit 23.1: Consent Of Pricewaterhousecoopers Llp
Exhibit 31.1: Certification Of Ceo Pursuant To Section 302
Exhibit 31.2: Certification Of Cfo Pursuant To Section 302
Exhibit 32.1: Certification Of Ceo Pursuant To Section 906
Exhibit 32.2: Certification Of Cfo Pursuant To Section 906
Ticker: ALXN
CIK: 899866
Form Type: 10-K Annual Report
Accession Number: 0000899866-13-000060
Submitted to the SEC: Tue Feb 19 2013 10:05:39 AM EST
Accepted by the SEC: Tue Feb 19 2013
Period: Monday, December 31, 2012
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/alxn/0000899866-13-000060.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...